Why Did CMND Stock Jump 40% Today?

• Clearmind said the patent covers formulations built around its proprietary MEAI formulation, which is also being used to develop treatments for weight loss and alcohol use disorder.
• Earlier this week, the firm received approval from the Johns Hopkins Medicine Institutional Review Board for its trial to treat alcohol use disorder.
• Clearmind had implemented a 1-for-10 reverse stock split earlier this month to meet Nasdaq’s minimum bid price requirement.

Clearmind Medicine (CMND) lit up the biotech space on Friday, with shares soaring around 40% after the company announced a patent filing in Japan for a non-hallucinogenic psychedelic-based therapy for depression.

CMND shares recorded their biggest single-day gains since the company implemented a 1-for-10 reverse share split earlier this month to meet Nasdaq’s minimum bid price requirement of $1.

Patent To Boost CMND’s Lead Therapy Pipeline

Clearmind said the patent covers formulations built around its proprietary molecule 5-Methoxy-2-aminoindan, or MEAI. The compound is Clearmind’s lead non-hallucinogenic therapy candidate, which is being developed as a safer and more accessible alternative to conventional antidepressants as well as psychedelic-based treatments.

The biotech firm is continuing to expand its MEAI-based drug pipeline, with research focused on alcohol use disorder, weight loss, and other mental health conditions.

Alcohol Use Disorder Treatment Gets Thumbs Up From Johns Hopkins

Earlier this week, Clearmind also received approval from the Johns Hopkins Medicine Institutional Review Board for its ongoing Phase I/II clinical trial of CMND-100. The drug is an MEAI-based oral candidate for the treatment of alcohol use disorder (AUD).

The trial showed that CMND-100 remained safe and well-tolerated, even at the highest doses. No serious side effects were reported in the third patient group, and the safety results were consistent with earlier stages of the study.

Clearmind has been on the investors’ radar since President Donald Trump signed an executive order last month to speed up the development and review of psychedelic-based therapies, including PTSD treatments such as Ibogaine, which the company is developing with SciSparc.

Retail Flags Bullish Technical Signal

Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes were ‘extremely high.

One user highlighted a bullish technical formation that could take the stock past $10.

The company has around one million outstanding shares, according to Koyfin data.

Read also: REPL Stock Shot Up 80% Today – What’s The Deal With FDA?

For updates and corrections, email newsroom[at]stocktwits[dot]com.